Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651294 | 0.83 | BCHE (0.40) | CRHR1MEN1KMT2ABCHEHRH3 | |
| SCHEMBL650098 | 0.82 | MEN1 (0.36) | CRHR1KDM4EMEN1KMT2ABCHE | |
| SCHEMBL650047 | 0.82 | C5AR1 (0.44) | CRHR1LMNAMEN1KMT2ABCHE | |
| SCHEMBL650987 | 0.82 | CALM1 (0.41) | CRHR1BCHE | |
| SCHEMBL651216 | 0.81 | CRHR1 (0.34) | CRHR1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL651053 | 0.80 | CA2 (0.40) | CRHR1 | |
| SCHEMBL5181418 | 0.80 | SMPD1 (0.40) | CRHR1LMNA | |
| SCHEMBL652209 | 0.78 | MEN1 (0.37) | CRHR1LMNAMEN1KMT2A | |
| SCHEMBL650495 | 0.77 | C5AR1 (0.52) | KDM4ELMNAKMT2ANPSR1 | |
| SCHEMBL5181407 | 0.77 | SMPD1 (0.41) | CRHR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014782-A1 | Combination therapy for the treatment of diseases involving inflammatory components | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-01-22 | — | — | US | claimed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014782-A1 | Combination therapy for the treatment of diseases involving inflammatory components | C5AR1, C5AR2, C3AR1 | CRHR1 229/4885KDM4E 4645/4885LMNA 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.